Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-siSSF-DC vaccine
- Development stage
- Unknown
- Lead developer
- Academy of Military Medical Sciences
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Ad-siSSF-DC is an adenovirus-based genetically modified dendritic cell (DC) vaccine developed by the Affiliated Hospital to Academy of Military Medical Sciences for the treatment of acute myeloid leukemia (AML). The vaccine utilizes an adenoviral vector (Ad-siSSF) to engineer monocyte-derived dendritic cells to express three functional components: a survivin-MUC1 fusion protein serving as tumor-associated antigens (TAAs), a SOCS1 short hairpin RNA (shRNA) that acts as an intracellular immune checkpoint inhibitor to override the SOCS1 molecule, and secretory bacterial flagellin which serves as a Toll-like receptor 5 (TLR-5) agonist to induce DC maturation. This biologic immunotherapy is designed to stimulate a potent anti-leukemic T-cell response and is frequently evaluated in clinical trials in combination with cytokine-induced killer (CIK) cells.
- Other names
- adenovirus-transfected dendritic cellsMUC1/Survivin-engineered DC vaccineAd-siSSF-transfected dendritic cells
02
Targets
BIRC5 (Survivin)MUC1 (Mucin-1 Antigen)TLR5SOCS1 (Suppressor of cytokine signaling 1)
Beyond the preview
Go deeper on Ad-siSSF-DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-siSSF-DC vaccine.